Surgery Partners reaffirms 2022 revenue and Adj. EBITDA guidance at J.P. Morgan conference

Surgery Partners, Inc.

Reaffirms 2022 revenue guidance of $2.50B to $2.55B.
Reaffirms 2022 Adjusted EBITDA guidance of $375M to $385M.
Guidance based on results through November 2022; year-end adjustments pending.
Management presenting at 41st Annual J.P. Morgan Healthcare Conference on Jan 9, 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Surgery Partners, Inc. reported the fiscal year ended December 31, 2022 results: revenue $2.50 billion to $2.55 billion. Guidance reaffirmed.

Period: the fiscal year ended December 31, 2022
Revenue: $2.50 billion to $2.55 billion
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Based on results through November 2022, the Company is re-affirming its 2022 Adjusted EBITDA guidance of $375 million to $385 million and its 2022 Revenue guidance of $2.50 billion to $2.55 billion.

View on SEC.gov

Browse all earnings releases →

Surgery Partners, Inc. filing history →

Source: SEC EDGAR

accession 0001638833-23-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.